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Abstract. Calotropis gigantea (L.) W. Aiton (C. gigantea) is a medicinal plant that has been 
empirically proven to have anticancer activity. In a previous study, it showed that the fraction of 
ethyl acetate from the root part of C. gigantea had higher anticancer activity than the other 
fractions. It suspected that the ethyl acetate fraction of C. gigantea root contained active 
compounds that has anticancer properties. This study aimed to determine the anticancer activity 
of active compounds from the ethyl acetate fraction of C. gigantea root regarding induction of 
apoptosis, cell cycle arrest, and expression of caspase-8 colon cancer cell WiDr. Isolation of the 
active compounds from the ethyl acetate fraction of C. gigantea root was carried out using 
Bioassay-guided Isolation method. Identification of active compounds was using NMR-1H, 
NMR-13C, HMBC, HMQC and UPLCMS/MS methods. The anticancer activity test of the 
identified compounds performed by using MTT method. The induction of apoptotic and cell 
cycle arrest evaluated by a flow cytometry method. The result of this study showed two active 
compounds were identified namely (1) (Pregnanon-5-en, 3,14,17 trihydroxy-12- (4'-cyclohexyl 
benzoate) -, (3β, 12β, 14β) - (9CI), (2) Pregn-5-en-20-one, 3,8,14-trihydroxy-12 - [(4'-hydroxy 
benzoyl) oxy] -, (3β, 12β, 14β, 17α) - (9CI). Both compounds inhibited the growth of colon 
cancer cell WiDr with IC50 values respectively were 15.89 μg/mL and 0.77 μg/mL. Both 
compounds increased the induction of apoptotic by increasing sub-G1, S, and G2-M following 
depletion of G0-G1 phase accumulation. 
1.  Introduction 
Calotropis gigantea (L.) W.T Aiton (C.gigantea) is a medicinal plant that grows in Indonesia. This plant 
has been traditionally used by Indonesian people as medicine to cure itching, scabies, boils, cough, 
trachoma, constipation (using its leaves), asthma, nausea, gastric pain (its flower), gonorrhea, bites of 
poisonous snakes (its root), toothache, swelling, ear inflammation, intestinal worms and dysentery [1]. 
Scientific evidence of its anticancer activity reported including the methanol extracts and the chloroform 
fraction of its flower that showed antitumor activity in mice with ascites carcinoma [2].  Methanol 
extract (ME) and chloroform fraction of its root were able to inhibit the growth of ascites carcinoma [3]. 
ICGT 2019






The cytotoxic potential of cardenolide compounds has also reported against MCF-7 breast cancer cells, 
skin cancer cells KB, lung cancer cells NCL-H18 [4]. Cytotoxic potency of dichloromethane of leaves 
extract on breast cancer cells MCF-7 and MDA-MB-231, Hela cells, HT-29 colon cancer cells, ovarian 
cancer cells SKOV-3, and hepatic cancer cells Hep-G2 [5]. C.gigantea leaf extract increased the efficacy 
of 5-Fluorouracil and decreased the effectiveness of Doxorubicin in Widr colon cancer cell culture [6]. 
In a previous study, it has also reported that the compound calotropin from the root part has cytotoxic 
activity against leukemia K562 and gastric cancer 7901[7]; the ethanol extract of C.gigantea leaves was 
able to inhibit fibrosarcoma growth in vivo by the mechanism of increased caspase-3 expression [8]. 
C.gigantea root extract has higher anticancer activity than the leaves and flower parts [9]. The ethyl 
acetate fraction of the leaf and dichloromethane fraction had higher cytotoxic activity than the butanol 
and water fractions [10]. Active compounds that have been successfully isolated from C.gigantea roots, 
including calotropin (1), frugoside (2) [7], afroside (3) ,15b-hydroxycalotropin (4), 15b-hydroxycalactin 
(5), calactin (6), calotoxin (7), 16a-hydroxycalactin (8), uscharin (9),  coroglaucigenin (10), 4’b,15b-
dihydroxycalactin (11), 15b-hydroxyuscharin (12), 5b-hydroxycalac-tinic acid methyl ester (13), 
calactinic acid ethyl ester (14), 15b-hydroxycalactinic acid ethyl ester (15) [11]. 
In our previous study, we had reported that the ethyl acetate root fraction of C. gigantea had cytotoxic 
activity against WiDr cells (IC50 0.063 μg/mL) which was higher than those in dichloromethane (IC50 
0.367 μg/mL), butanol (IC50 0.18 μg/mL) and water (IC50 2.24μg/mL) [10]. Our previous study also 
showed that ethyl acetate fraction of C. gigantea roots induced apoptosis through increased G2/M and 
increased expression of caspase-8 in colon cancer WiDr cell line [12]. 
Based on these studies it is suspected that there are active compounds in the ethyl acetate fraction of 
C.gigantea root that play a significant role in the anticancer activity. In this study, the isolation of active 
anticancer compounds from the fraction of ethyl acetate of C. gigantea root was carried out using 
Bioassay-guided isolation approach to WiDr cell and the working mechanism of the active compound 
is described through induction of apoptosis and Cell cycle arrest. 
2.  Material and methods 
2.1.  Material   
Roots of C. gigantea obtained from the city of Malang, East Java tool-type and determination was 
carried out in LIPI Purwodadi, East Java, Indonesia. A specimen voucher (No. 201303) deposited at the 
Phytochemistry laboratory of Maulana Malik Ibrahim State Islamic University. 
2.2.  Ethical Approval  
The study approved by The Ethical Committee of Faculty of Medicine, Brawijaya University, certificate 
number: 425-KEP-UB, Date: May 24th, 2015. 
2.3.  Extraction and Isolation of active compounds 
The active compound was obtained from several stages of separation using bioassay-guided isolation 
approach.  Dried powder of the root (5 kg) was extracted by maceration using ethanol 70%. The ethanol 
extract (214.5 g) was further fractionated by the liquid-liquid partition method using dichloromethane, 
ethyl acetate, butanol and water as solvents. The obtained fractions (F1-F4) tested for the anticancer 
activity in vitro using colon cancer cell WiDr. Furthermore, the most active fraction (F2) i.e. ethyl 
acetate fraction (16.02 g) was separated for its active compound by vacuum column chromatography 
using silica gel G 60 as a stationary phase and gradient mobile phase CHCl3: CH3OH (100: 100 - 50:50), 
where 7 subfractions (SF1-SF7) obtained. The IC50 data in table 1 showed that SF3 has the lowest IC50 
value (6.09µg/mL). An open column chromatography further separated the most active subfraction 
(SF3: 280 mg) with silica gel 60 and mobile phase were hexane and ethyl acetate (4: 1); ethyl acetate: 
chloroform (9: 1); and chloroform: methanol 1: 1. In this separation, two single stains called compound 
1 (10 mg), and compound 2 (15 mg) obtained. The results of anticancer activity assays of SF1-SF7 were 
presented in table 1. 
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2.4.  Identification of isolates 
Mass spectra of active isolates were obtained using UP-LCMS / MS tool-type ACQUITY UPLC I-Class 
(Waters, United Kingdom) with detector diode-array detector (DAD) 2996 (waters); column: Sunfire 
C18, p 50 mm, diameter 2 mm, particle size μm (Waters). Mobile phase: acetonitrile gradient; water; 
acid format, flow rate 1ml / min, injection volume 10 ul. MS system Xevo G2-S QTOF (Waters), 
analyzer: TOF with positive electrospray (ES +), gas flow 794 L/min. NMR spectra; HMQC, HMBC 
(for 2D NMR) obtained by NMR JEOL ECS400 (400 MHz), CDCl3 as solvent and TMS as an internal 
standard.  
Table 1. Values of IC50 of SF1-SF7 Treatments on the Growth of WiDr Colon Cancer Cells. 
Groups/dose 
Mean of Viability WiDr Cells Line at  treatment 
concentration (μg/mL)   
IC50 (μg/mL)  ±    
SD* 
200 100 50 25 12.5 6.25 3.75 0.935 
SF1 25.16 31.78 40.43 60.54 65.06 74.52 78.69 83.89  32.38    ±    2.32 
SF2 45.43 48.78 49.54 59.26 46.69 64.42 77.59 87.92  59.53    ±    9.51 
SF3 1.82 3.10 4.52 8.72 50.89 60.32 64.82 76.79    6.09    ±    0.08 
SF4 3.58 7.88 15.21 31.69 55.67 69.91 73.11 86.97  11.05    ±    1.96 
SF5 34.17 44.22 54.74 64.22 61.40 73.27 83.84 85.91  60.72    ±    2.74 
SF6 39.41 45.78 59.88 69.69 82.07 85.27 89.11 88.91 103.27   ±    9.63 
SF7 22.83 28.35 32.55 42.46 51.82 65.46 73.89 89.46   18.66    ±    2.85 
*Average value of IC50 ± SD in triplicates  
2.5.  Anticancer activity Test 
Compound 1 and 2, were tested for their anticancer activity in vitro using colon cancer cells of WiDr. 
Anticancer activity expressed as IC50. Cell viability was determined using MTT assay. The cytotoxic 
test stages were carried out according to the protocol of CCRC-UGM [13].   
2.6.  The apoptotic induction test 
The mechanism of action of the anticancer activity determined by three parameters: cell cycle regulation, 
induction of cell apoptosis and caspase-8 expression. Cell cycle regulation was analyzed using 
fluorescence-activated cell sorting method using propidium iodide (PI) probe. The induction of cell 
apoptosis also determined by using a flow cytometer with a combination of PI-Annexin V reagents. 
Immunocytochemical methods observed Caspase-8 expression. The stages of apoptotic induction testing 
performed according to the protocol of CCRC-UGM [14]. 
2.7.  Cytotoxicity Test Using MTT Assay 
The suspension of colon cancer cells WiDr (100 μL) contains 3×104 cells / 100 μL of medium was 
distributed into wells on a 96-well plate and incubated for 24 hours. After incubation, 100 μL of the test 
solution added into the well, at a series of concentrations. As a positive control, 100 μL of culture 
medium added, then 100 μL of cisplatin at series concentration into the wells. As a cell control, 100 μL 
of culture medium attached to the well containing 100 μL of cell suspension. For a solvent control, 100 
μL of DMSO added to the well containing 100 μL of culture medium and 100 μL of the cell suspension 
with the same serial dilution corresponding to those of the test solution. They incubated for 24 hours at 
5% CO2 and 95% O2. At the end of incubation, medium removed, and 10μL of MTT solution (5 mg/mL 
PBS) added, and the medium replaced with 190 μL complete RPMI 1640 medium. Cells incubated for 
3-4 hours. The MTT reaction stopped with the addition of SDS stopper reagent (100 μL). The microplate 
was then wrapped in tissue paper and incubated overnight in dark room at room temperature. Live cells 
react with MTT to form a purple color. The test results were read using ELISA reader at a wavelength 
of 595 nm [14]. 
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2.8.  Analysis of cell cycle with flow cytometry 
In this cell cycle analysis, Propidium Iodide (PI) used as a dye to analyze the number of DNA sets in 
each cell. Cells of 5x105cell/well were incubated in 6-well plate. Cells treated with DMSO (0.25%) and 
active isolates at its IC50. The cells were then reincubated for 24 hours. At the end of the incubation, the 
medium was removed and transferred into a tube and centrifuged (2000 rpm, 3 min). The supernatant 
removed. PBS added to the wells where the medium removed, and moved to the same microtube, 
centrifuged and the supernatant discarded. This step repeated once again, and the cells were harvested 
with trypsin. Cells were transferred into the same microtube then centrifuged at 2000 rpm, for 3 min. 
The rest of the harvesting cells in the well were rinsed with PBS and centrifuged again, and the PBS 
discarded. The cell precipitates in the microtube then fixed with 70% ethanol, -20 °C, incubated for 30 
min at room temperature or overnight at 4 °C, then centrifuged (2000 rpm, 3 min). The cell precipitate 
washed with PBS 2 times and then PI reagents were added and immediately homogenized. The 
microtube containing the cell suspension is wrapped in aluminum foil and incubated in a 37 °C water 
bath for 20 minutes. The cell suspension was homogenized again and transferred into a flow cytometer 
tube using a nylon filter, and ready to be analyzed.   
2.9.  Analysis of cell apoptosis induction using flow cytometry 
Cells were plated in 6-well plate (5×105cells / well) and treated with DMSO (0.25%) and the active 
isolates. The cells were then re-incubated for 24 hours. At the end of the incubation, the medium was 
removed and transferred into a tube and centrifuged (2000 rpm, 3 min.) and then the supernatant 
discarded PBS was added to the well and assigned to the same microtube, centrifuged again. The 
supernatant discarded. This step repeated once again, and the cells were harvested with trypsin. Cells 
were transferred into the same microtube and centrifuged (2000 rpm, 3 min.). The rest of the harvesting 
cells were rinsed with PBS and centrifuged again, and the PBS discarded. To the precipitates, PI-
Annexin V reagents were added and immediately homogenized. The microtube containing the cell 
suspension was wrapped in aluminum foil and incubated in a water bath at 37 °C for 5 minutes. The cell 
suspension was homogenized again and transferred into a flow cytometer tube using a nylon filter, and 
ready to be analyzed. 
3.  Results and discussion  
3.1.  Identification of Compound 1 
Compound 1 was a colorless gel-shaped compound. Chromatogram profile UPCLMS/MS of compound 
1 with a C18 Sunfire stationary phase and a mobile phase of gradient acetonitrile: water: Formic acid 
gave a single peak at retention time of 14.24 minutes with the dominant area under the curve. The mass 
spectrum of compound 1 showing the molecular ion m/z 522.3380 (measured mass), while the calculated 
mass of compound 1 based on ChemDraw buffer was m/z 522.3345. In conclusion, the molecular 
formula of compound 1 is identical to C33H46O5. The result from nuclear magnetic resonance 
spectroscopy NMR-1H showed the number of protons and chemical shift positions (δ) indicating the 
type of proton in compound 1 is δ = 1.59 (proton CH3, 3H, singlet); δ = 2.203 (CH3, 3H, singlet); δ = 
2.77 (-CH cyclohexane, 1H, multiplet); δ = 3.651 (OH alcohol, 3H, singlet overlapped); δ = 4.216 (-CH 
cyclohexane, 1H, triplet)  δ =5.341 (-CH cyclohexane, 1H, singlet); δ = 7.53/C3’ (=CH benzene, 1H, δ 
= 7.54/C5’ (=CH benzene, 1H, triplet) triplet); δ = 7.716/C2’ (=CH benzene, 1H, triplet); δ = 7.714/C5’ 
(=CH benzene, 1H, triplet). The presence of cyclohexane substitution is indicated by δ= 2.287/C22 (-
CH, 1H, triplet); δ=1.668/C23 (-CH2, quartet), δ = 1.653/C27 (-CH2, quartet); δ=1.289 (-CH2, 
multiplet); δ=1.285 (-CH2, multiplet); δ=1.29 (-CH2, multitaplet). Based on NMR-13C magnet 
resonance spectroscopy data and chemical shift position (δ) showed the type of carbon in compound 1 
is : δ = 167.886 (-COO, C carboxyl); δ =132.503 (=C-C; C benzene); δ =130.997 (=C-C; CH benzene); 
δ=128.890(=C-C; CH benzene); δ= 68.231 (O-C-C; CH cyclohexane); δ= (O-C-C; CH cyclohexane); 
δ=41.074 (C-C-C; C cyclohexane); δ= 38.778 (C-C-C; C cyclohexane); δ=34.202 (C-C-C; C 
cyclohexane)  δ= 32.028 (C-C-C; C cyclohexane) δ=30.414; δ=29.797; δ= 29.463; δ=29.358; δ=29.253; 
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δ= 29.215; δ=29.006; δ=27.229; δ=25.039  (CH2 cyclohexane) ; δ=23.800; δ=23.085; δ=22.798 (CH2 
cyclopentane); 14.179 (CH3 aliphatic); 11.061 (CH3 aliphatic). The proton and carbon shifts showed 
that compound 1 is identical to pregnanon-5-en, 3,14,17 trihydroxy-12-(4’-syclohexylbenzoyl)oxy-, 
(3β,12β,14β)-(9CI).  
The proton and carbon shifts showed that compound 1 is identical with the pregnanon-5-en, 3,14,17 
trihydroxy-12- (4'-cyclohexylbenzoyl) oxy-, (3β, 12β, 14β) - (9CI) compounds. The compound has a 
core structure of pregnanone, and there were additional substitutions of cyclohexane in 4 
benzene/cyclohexyl benzoyl. The carbon and proton chemical shift and proton of the isolate of 
compound 1 and the correlation of carbon with proton presented in Table 2 and Figure 1: 
 
Table 2. The chemical shift of carbon and proton of isolates of compound 1 and the correlation of carbon 
with protons. 
C δ H (400 Hz) δ C (400 HZ) HMBC 
1  1.745 (1H, m), 1.11 (1H,m)  30.41  C2, 3, 5, 10 
2  1.594, 1.30 (1H,m)  29.46 C3, 4, 10 
3  3.65 (2H, s) , 3.45 (1H,s)  68.231 C1, 2, 5 
4  2.306 (1H, dd), 2.25 (1H, overlapped)   C2, 6, 5, 10 
5  .      
6  5.361 (1H, m)   C4, 5, 7, 10 
7  2.26, 1.984 (each 1H, m, J=0.47)   25.8  C5,6,9, 14 
8  1,844 (1H,m)   34.2  C7, 10, 14 
9  1.316 (1H, m)   38.77 C1, 5, 11, 12,14 
10      29.79   
11  2.001, 1.984 (1H,m, overlapped)   23.08 C8, 10,13 
12  4.229 (1H, dd)      C7’ 
13      41.07   
14      51.57   
15  2.15, 1.98 (each 1H,m)    29.21  C8, 13,16,17 
16  2.806 (1H,m), 1.88 (1H,m)   29.25 C13,14,20 
17      68.23    
18  1.30 (3H,S)   11.06  C-12,13,14 
19  0.903 (9 H, m)   14.18 C-1,5,9,10 
20   1.29 (1H,s)   27.29   
8’ 2.287 (triplet)  41.08  
9’, 13’ 1.668; 1.653 (2H,dd)  29.0 C-12’,C9’, C10’ 
10’, 12’ 1.289; 1,285 (13H, dd)  22.7 C-9’, C10 
11’ 1.29 (13H,m)  23.8  
1'      132.503    C2’, 6’ 
2' ,6’ 7.716 (1H,d)   130.99  C1’,3’, 4’,6’/2’  
3' , 5’ 7.52(1H,t)   128.89  C1’,2’, 4’, 5’/3’ 
4'    128.117 C1’, 2’, 5’,6’ 
7'      167.886    
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Figure 1. HMBC chemical structure of compound 1: pregnanon-5-en, 3,14,17 trihydroxy-12-(4’-
cyclohexylbenzoyl)oxy-, (3β,12β,14β)-(9CI). 
3.2.  Identification of Compound 2 
Compound 2 was a white needle crystal. The mass spectrum of compound 2 showed the measured mass 
at m/z 484.2460. The calculated mass of compound 2 was m/z 484.2461 which corresponds to the 
molecular formula of C28H36O7. The nuclear magnetic resonance spectroscopy NMR-1H showed the 
number of protons and the chemical shift position (δ) indicated the proton type in compound 2 is  
δ/C2’,6’ = 7.71 (=CH benzene, 1H, dd), δ/3’,5’ = 7.52 (=CH benzene, 1H, dd), the presence of OH in 4 
'benzene carbon is shown by δ/C4' =5.93 (=OH benzene, 1H, s);  δ/C1 =1,61; 1.23 (-CH2 cyclohexane, 
m),  δ/C2 = 1.61; 1.26 (-CH2 cyclohexane, m). The presence of a hydroxyl proton at the pregnanone 
core indicated by the shift of the proton at δ/C3= 3.47(-OH cyclohexane, 1H, singlet) ; δ/ C8, C14 =3.65 
(-OH cyclohexane, 2H, singlet), the presence of a methyl proton at the pregnanone core was indicated 
by δ/C6 = 5.27 (=CH cyclohexane,1H, s), δ/C4,C7,C15,C16= 2.035 (-CH2 cyclohexane, 4 H, m), δ= 
4.22 (-CH-COO, triplet), δ=2.612(-CH-CO cyclopentane, triplet ). The chemical shift and the number 
of protons were identical to the compound pregn-5-en-20-one, 3,8,14-trihydroxy-12-[(4’-hydroxy 
benzoyl)oxy]-, (3β,12β,14β,17α)-(9CI). Based on the number of protons, the position of the proton 
chemical shift, and molecular weight and the fragmentation of molecular ions, it can be concluded that 
compound 2 (SF 2.4.2) was identical with the compound of pregn-5-en-20-one, 3,8,14-trihydroxy-12-
[(4'-hydroxy benzoyl)oxy]-, (3β,12β,14β,17α)-(9CI). The chemical shift and structure of the compound 
are presented in Table 3 and Figure 2. The chemical shift and structure of the compound have similarities 
to the compounds in the previous studies [15]. 
3.3.  Anticancer activities of Compound 1 and 2 
The effectiveness of anticancer of compound 1 and 2 tested by MTT assay. Table 1 shows the increased 
concentration of the compound 1, ie. (pregnanone-5-en, 3,14,17 trihydroxy-12-(4’-cyclohexyl 
benzoyl)oxy-, (3β,12β,14β)-(9CI)) and compound 2 ie. pregnanone-5-en-20-one, 3,8,14-trihydroxy-12-
[(4'-hydroxy benzoyl)oxy]-, (3β,12β,14β,17α)-(9CI) can lead to decreased viability of WiDr cells. From 
the value of IC50, it showed that compound 2 has a stronger anticancer activity than compound 1. The 
percent viability of WiDr cells and IC50 average of compound 1 and compound 2 presented in table 4. 
3.4.  Cell cycle inhibition 
To determine whether the antiproliferative effect caused by the treatment of compounds 1 and two that 
leads to a resting phase, further analysis of changes in the distribution of WiDr cancer cell cycle is 
required. Cell cycle analysis was performed by fluorescence-activated cell sorting method using 
propidium iodide (PI) probe. The results of cell cycle analysis of WiDr cancer due to the treatment of 
compound 1 and compound 2 are presented in Figure 3. 
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Table 3. Proton shift of compound 2 of ethyl acetate fraction of the C.gigantea root.  
H Compound 2 Reference [15] 
1 1.61 m; 1.23 m 1.72 m; 121 m 
2 161 m; 1.26 m 1,75 m; 125 m 
3 3.65 m 3.69 m 
4 2.31 m ; 2.03 2.31 m; 2.03 m 
6 5.27 s 5.28 brs 
7 2.03 m 2.03 m 
8 3.65 s 3.65 s 
9 1.32 dd 1.46 dd 
11 1.88 m; 1.61 m 1.88 m; 1.67 m 
12 4.22 dd 4.74 dd 
14 3.65 s 3.65 s  
15 2.03 m; 1.58 m 1.99 m; 1.58 m 
16 2.03 m; 1.61 m 2.03 m; 1.63 m 
17 3.4 s 3.2 s 
18 1.26 s 1.59 s 
19 0.92 s 1.03 s 
21 2.03 s 1.96 s 
2',6' 7.71 dd 7.86 dd (8.0, 1.6) 
3',5' 7.52 dd 7.52 dd 
4' 5.9 s 5.35 s 
 
Figure 2. Chemical Structure of Compound 2: Pregnanone-5-en-20-one, 3,8,14-trihydroxy-12-[(4’-
hydroxybenzoyl)oxy]-, (3β,12β,14β,17α)-(9CI). 
Table 4. Percent of WiDr cell viability and IC50 of compound 1 and compound 2.  
Compound Cell viability (%)±SD at  treatment concentration (μg/ml) IC50 (µg/ml) 
± SD 0 0.78 12.5 25 50 
1 100±0 27.37 ± 1.04 33.54 ± 1.04 42.31 ± 2.45 49.64 ± 9.27 15.89±1.36 
2 100±1 70.01 ± 0.16 23.28 ± 3.01 26.41 ± 8.53 26.68 ± 4.16 3.18  ±0.69 
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3.5.  Cell cycle inhibition 
To determine whether the antiproliferative effect caused by the treatment of compounds 1 and two that 
leads to a resting phase, further analysis of changes in the distribution of WiDr cancer cell cycle is 
required. Cell cycle analysis was performed by fluorescence-activated cell sorting method using 
propidium iodide (PI) probe. The results of cell cycle analysis of WiDr cancer due to the treatment of 
compound 1 and compound 2 are presented in Figure 3. 
3.6.  Induction of apoptosis 
Observation of apoptotic induction was performed to determine the cause of cell death for both apoptosis 
and necrosis. The flow cytometry method can distinguish living cells, early apoptosis, late apoptosis, 
and necrosis because the reagents Annexin V and PI work selectively bind to whole cells or those that 
not intact (fragmentation). The results of the apoptotic induction test with flow cytometry presented in 
Figure 4. Inhibition of proliferation may be caused by modulation in cell cycle and by the induction 
apoptosis. The data of IC50, G2 / M phase, apoptosis of colon cancer cell WiDr as the results of treatment 
with compound 1 and 2 presented in table 4.  
The purpose of isolation and identification of anticancer compounds in this study was to obtain an 
active anticancer compound from C. gigantea root F2. This isolation identified by using bioassay-guided 
isolation method, i.e., separation of an active anticancer compound from C.gigantea root extract which 
guided its anticancer activity from fraction, subfraction up to its isolate. Isolates were known to be active 
as anticancer identified by their chemical structure using nuclear magnetic resonance spectra of proton 
and carbon (NMR-1H, NMR-13C)  recorded with JOEL ECS-400 spectrometer and electrospray mode 
(ES +) mass spectra obtained by UPLCMS/MS. 
Anticancer activity test was performed in vitro using colon cancer cell WiDr. Selection of cancer 
cells based on previous research where there was still no report on the anticancer activity of an active 
compound from the root C.gigantea. The characteristic of these cancer cells was the high expression of 
cyclooxygenase-2 (COX-2) that stimulates the proliferation of WiDr cells [16]. In the WiDr cell, there 
was a p53 G mutation at a position of 273 resulting in a change in arginine residue to histidine [17]. 
However, p21 in normal WiDr cells allows for the cessation of cell cycles [18]. Apoptosis in WiDr cells 
can occur via the independent pathway of p53, including through p73 activation [19]. Based on the 
results of the above analysis, this study found 2 active anticancer compounds consisting of one novel 
compound (pregnanone-5-en, 3,14,17 trihydroxy-12- (4'-cyclohexyl benzoyl) -, (3β, 12β, 14β ) - (9CI), 
and 1 known compound (1) Pregn-5-en-20-one, 3,8,14-trihydroxy-12 - [(4'-hydroxy benzoyl) oxy] -, 
(3β, 12β, 14β, 17α) - (9CI) . The two compounds belonged to the triterpenoid group with the pregnanon 
core and may inhibit the growth of colon cancer cell WiDr by induction of apoptosis and cell cycle 
inhibition. 
Treatment at the dosage of IC50 for compound 1 (15.89 μg / ml) and compound 2 (3.81 μg / ml) in 
the proliferation of WiDr cells caused cell cycle changes with increasing of sub-G1, S, and G2-M 
following depletion of G0-G1 phase accumulation compared to control cells (Fig 3). Distribution 
changes in the cell cycle after the treatment will direct the cell to rest at a particular phase in the cell 
cycle, causes the induction of cell death. Those against cancer cell WiDr created increase apoptosis 
consecutively 19.43% and 12.96% compared to control (4.6%). The increase of apoptotic induction of 
both compounds was significantly different from control (p <0.001).   
The decreased of the cell accumulation in G0-G1 phase colon cancer cell WiDr due to the therapy of 
compound 1 and compound 2, was suspected result of the apoptosis induction by both compounds 
through activation of P53. In previous studies, it has found that triterpenoid compounds can induce 
apoptosis through activation of P53 [19]. At the G1/S checkpoint, the damage of DNA could trigger cell 
cycle arrest, and this process was p53-dependent. In general, the low levels of p53 in a cell were 
negatively regulated by MDM2 which targeting the degradation of p53, but DNA damage could induce 
p53 activity rapidly [20]. P53 is a transcriptional factor in the formation of p21. Increased p21 will 
suppress all CDC (Cyclin-Dependent Kinase) with cyclin, where the cell division cycle is highly 
dependent on complex bonds between CDK and cyclin.  In case of binding of p21, all CDK will be 
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suppressed both CDK-1 in phase M and CDK-4 and CDK-6 in phase S, the cell cycle will stop so that 
p53 will trigger Bax activity. Bax protein will suppress the activity of Bcl-2; therefore the mitochondria 
membrane permeability changes resulting in a release of cytochrome c into the cytosol and it will 
activate caspase cascade. This active caspase will activate the DNAse, penetrate the nuclear membrane, 




Figure 3. The induction effect of cell death and changes in distribution at the cell cycle phase against 
WiDr cells as results of treatment at the dose of IC50 with compound 1 and compound 2. Statistically 
significant differences (p<0.01) as compared to control in Sub G1 and G0-G1 phases. (A) control; (B) 
compound 1; (C) compound 2. 
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Figure 4. Cell distribution and analysis of cell death induction using Flowcytometry (A) control of 
WiDr cell (B) treatment with compound 1; (C) treatment with compound 2 against WiDr cells: (R1) 
live cell (R2) cell apoptosis (R3) ) late apoptosis, and (R4) necrosis. 
 
Table 4. IC50 data, G2/M phase, apoptosis of colon cancer cell WiDr due to treatment with compound 
1 and 2. 



















3.18 19.67 15.55 21.2 12.86 
4.  Conclusion 
Two active compounds from the ethyl acetate fraction of C.gigantea root were obtained consisting of 
one novel compound pregnanone-5-en, 3,14,17 trihydroxy-12-(4'-cyclohexyl benzoyl)oxy-, 
(3β,12β,14β)-(9CI), and one known compound that has not been reported found in C.gigantea,  
pregnanone -5-en-20-one,3,8,14-trihydroxy-12- [(4'-hydroxy benzoyl)oxy]-,  (3β,12β,14β,17α)-(9CI)). 
Compound 1 (IC50: 15.89 μg/ml) and 2 (IC50: 3.18 μg/ml) may induce apoptosis of colon cancer cell 
WiDr with increasing of sub-G1, S, and G2-M following depletion of G0-G1 phase accumulation 
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Figure S1.  HNMR spectra of compound 1 analyzed with NMR JEOL ECS400 (400 MHz) using 
CDCl3 as solvent and  TMS as internal standart. 
 











   Figure S3. HMQC of compound 1. 
 





















Figure S5.  Profile of chromatogram UPLCMS / MS with stationary phase of Sunfire C18 2 2 x 50 
mm column, and fixed mobile phase of ACN: H2O: formic acid, flow rate of 1 ml / min (a) isolate 3.1 
root of C. Gigantea single peak chromatogram at retention time of 14.22 min identified as molecule 





















































Figure S7. HNMR Spectra of isolate 3.4.2 from the root part of Calotropis gigantea, 5 mg sample 












Figure S8. Profile of Chromatogram UPLCMS / MS with stationary phase of Sunfire C18 2 2x 50 
mm column, and mobile phase Gradient of ACN: H2O, flow rate 1 ml / min (a) isolate 3.4.2 from 
Roots of Calotrophic gigantea, single peak at retention time of 13.09 min, identified as molecule with 
formula of C28H36O7, m/z 484.2460. 
C28H36O7 
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Figure S9. spectra m/z of compound 2. 
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